title: Moclobemide in the treatment of hot flashes in postmenopausal women.
abstract: This randomized, prospective, double-blind study evaluated the efficacy and tolerability of moclobemide, a reversible, selective inhibitor of monoamine oxidase-A, in reducing the frequency and severity of hot flashes. Thirty postmenopausal women were enrolled, and 28 were allocated to 5 weeks of treatment with moclobemide 150 mg (group 1, n = 10), moclobemide 300 mg (group 2, n = 11), or placebo (group 3, n = 9). Data on hot flashes were recorded in a daily diary. Mean reductions in the hot flash severity score were 24.4% in the placebo group, 69.8% in group 1, and 35.0% in group 2. This large difference suggests that the beneficial effects were not due to a placebo effect. Moclobemide may be a new nonhormonal option for reducing the incidence, severity, and duration of hot flashes in postmenopausal women who do not wish to take estrogen or have contraindications to its use.
authors.affiliation: Başkent University Faculty of Medicine, Department of Obstetrics and Gynecology, Seyhan-Adana, Turkey.
authors.forename: Ebru
authors.initials: E
authors.lastname: Tarim
authors.forename: Tayfun
authors.initials: T
authors.lastname: Bagis
authors.forename: Esra
authors.initials: E
authors.lastname: Kilicdag
authors.forename: Serkan
authors.initials: S
authors.lastname: Erkanli
authors.forename: Erdogan
authors.initials: E
authors.lastname: Aslan
authors.forename: Esra
authors.initials: E
authors.lastname: Kuscu
mesh_terms: D000328:Adult; D000704:Analysis of Variance; D004305:Dose-Response Relationship, Drug; D004311:Double-Blind Method; D005260:Female; D019584:Hot Flashes / Q000188:drug therapy*; D006801:Humans; D008875:Middle Aged; D020912:Moclobemide / Q000494:pharmacology / Q000627:therapeutic use*; D008996:Monoamine Oxidase Inhibitors / Q000494:pharmacology / Q000627:therapeutic use*; D017698:Postmenopause; D011446:Prospective Studies
chemical_list: D008996:Monoamine Oxidase Inhibitors; D020912:Moclobemide